LPCN lipocine.com Earnings growth forecast for next year
Lipocine Inc. remains resilient to market volatility driven by demand for innovation in metabolic therapy. This chart of the consensus EPS n+1 forecast visualizes current trends, while the 11.10 metric indicates the status of expectations. Growth potential is supported by licensing payments from industry behemoths and a team of leading biochemists attracted by research autonomy and share value.
LPCN (Lipocine Inc): analytical breakdowns and indicator data
- share price and consensus valuation forecast:
- market capitalization data:
- book capitalization indicators:
- debt and solvency information:
Total Debt to Capital Lipocine Inc.|LPCN - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Lipocine Corporation|LPCN - Company Total Debt Obligations|Debt to Book Capitalization Ratio Lipocine Corp|LPCN - Company Long-Term Liabilities|Company Short-Term Debt Lipocine|Quick Ratio lipocine.com
- net income and valuation ratios data:
LPCN - Net Financial Result|Expected Profit Lipocine Inc.|LPCN - Market Cap to Net Income|Future Price to Earnings Lipocine Corporation|LPCN - Price to Earnings Adjusted for Growth Rate|EV/EBITDA Multiple Lipocine Corp|LPCN - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Lipocine|LPCN - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months lipocine.com|LPCN - Earnings per share growth this year|Earnings growth forecast for next year Lipocine Inc.
- total revenue and sales volume data:
Initial company analysis:LPCN, lipocine.com
The investment attractiveness of Lipocine Inc. (LPCN) is determined by the balance between its innovative delivery technology and FDA regulatory risks. This indicator measures the expected earnings per share (EPS) dynamics, aggregating analyst forecasts for future profitability amid cost of capital volatility. By analyzing the current trajectory of next year's EPS forecasts, an investor can assess the probability of drug commercialization and the resilience of the stock price to potential approval delays.
Analysis of competing companies
ASND (Ascendis) - Earnings growth forecast for next year|Earnings growth forecast for next year Madrigal Pharmaceuticals|Earnings growth forecast for next year CORT|Net earnings per share growth forecast for next year RYTM (Rhythm Pharma)|Net earnings per share growth forecast for next year akerotx.com AKRO|Metsera Therapeutics (MTSR) - Expected net earnings per share growth next year|MLTX - Net earnings per share growth forecast for next year|CRNX: Net earnings per share growth forecast for next year|NAMS: Earnings growth forecast for next year|SLNO - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Amicus Corp|89bio Pharma (ETNB) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year agios.com (AGIO)|Expected earnings per share growth for next year structuretx.com GPCR|Net earnings per share growth forecast for next year MiMedx Group Inc MDXG|Expected earnings per share trend next year RZLT|lexpharma.com - Earnings growth forecast for next year|MBX (MBX Biosciences Inc) - Projected earnings per share growth rate for next year|ALT: Earnings growth forecast for next year|Aardvark Therapeutics Inc - Expected earnings per share trend next year|SGMT (Sagimet Biosciences, Inc.) - Earnings growth forecast for next year|Earnings growth forecast for next year BioAge|Earnings growth forecast for next year BMEA|Expected earnings per share growth for next year Quince Therapeutics, Inc. QNCX|Fractyl Health Inc. - Expected earnings per share growth for next year|Expected earnings per share trend next year VTVT|Agape ATP Corporation - Earnings growth forecast for next year|Consensus forecast of earnings per share growth for next year Pluri PLUR|SYBX: Earnings growth forecast for next year|Matinas BioPharma Holdings, Inc. - Expected earnings per share trend next year|SPRB (Spruce Biosciences Inc.) - Earnings growth forecast for next year|galecto.com (GLTO) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Carmell Therapeutics (CTCX)|LUMO (Lumos Pharma Inc) - Expected earnings per share trend next year|Net earnings per share growth forecast for next year organovo.com ONVO|Radius Health (RDUS) - Expected net earnings per share growth next year
